Increased circulating and epicardial adipose tissue mrna expression of fibroblast growth factor-21 after cardiac surgery: Possible role in postoperative inflammatory response and insulin resistance

Physiological Research

Volumn 60, Issue 5, 2011, Pages 757-767

  Kotulak T ^a   Drapalova J ^b   Kopecky P ^b   Lacinova Z ^b   Kramar P ^a   Riha H ^a   Netuka, I ^a   Maly J ^a   Housa, D ^c   Blaha J ^b   Svacina S ^b   Haluzik M ^b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adipose tissue; Cardiac surgery; Fibroblast growth factor 21; Insulin resistance; Skeletal muscle

Indexed keywords

EID: 84856493734     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: 10.33549/physiolres.932134     Document Type: Article

References (24)

1. BADMAN MK, PISSIOS P, KENNEDY AR, KOUKOS G, FLIER JS, MARATOS-FLIER E: Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5: 426-437, 2007.
2. BAKER AR, SILVA NF, QUINN DW, HARTE AL, PAGANO D, BONSER RS, KUMAR S, MCTERNAN PG: Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 5: 1, 2006.
3. BLAHA J, KOPECKY P, MATIAS M, HOVORKA R, KUNSTYR J, KOTULAK T, LIPS M, RUBES D, STRITESKY M, LINDNER J, SEMRAD M, HALUZIK M: Comparison of three protocols for tight glycemic control in cardiac surgery patients. Diabetes Care 32: 757-761, 2009.
4. CHEN WW, LI L, YANG GY, LI K, QI XY, ZHU W, TANG Y, LIU H, BODEN G: Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116: 65-68, 2008.
5. DOSTÁLOVÁ I, KAVÁLKOVÁ P, HALUZÍKOVÁ D, LACINOVÁ Z, MRÁZ M, PAPEZOVÁ H, HALUZÍK M: Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 93: 3627-3632, 2008.
6. FAZELI PK, MISRA M, GOLDSTEIN M, MILLER KK, KLIBANSKI A: Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. J Clin Endocrinol Metab 95: 369-374, 2010.
7. FINFER S, CHITTOCK DR, SU SY, BLAIR D, FOSTER D, DHINGRA V, BELLOMO R, COOK D, DODEK P, HENDERSON WR, HEBERT PC, HERITIER S, HEYLAND DK, MCARTHUR C, MCDONALD E, MITCHELL I, MYBURGH JA, NORTON R, POTTER J, ROBINSON BG, RONCO JJ: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360: 1283-1297, 2009.
8. GALMAN C, LUNDASEN T, KHARITONENKOV A, BINA HA, ERIKSSON M, HAFSTROM I, DAHLIN M, AMARK P, ANGELIN B, RUDLING M: The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 8: 169-174, 2008.
9. HOJMAN P, PEDERSEN M, NIELSEN AR, KROGH-MADSEN R, YFANTI C, AKERSTROM T, NIELSEN S, PEDERSEN BK: Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 58: 2797-2801, 2009.
10. INAGAKI T, CHOI M, MOSCHETTA A, PENG L, CUMMINS CL, MCDONALD JG, LUO G, JONES SA, GOODWIN B, RICHARDSON JA, GERARD RD, REPA JJ, MANGELSDORF DJ, KLIEWER SA: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217-225, 2005.
11. IZUMIYA Y, BINA HA, OUCHI N, AKASAKI Y, KHARITONENKOV A, WALSH K: FGF21 is an Akt regulated myokine. FEBS Lett 582: 3805-3810, 2008.
12. JOHNSON CL, WESTON JY, CHADI SA, FAZIO EN, HUFF MW, KHARITONENKOV A, KOESTER A, PIN CL: Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 137: 1795-1804, 2009.
13. KHARITONENKOV A, SHIYANOVA TL, KOESTER A, FORD AM, MICANOVIC R, GALBREATH EJ, SANDUSKY GE, HAMMOND LJ, MOYERS JS, OWENS RA, GROMADA J, BROZINICK JT, HAWKINS ED, WROBLEWSKI VJ, LI DS, MEHRBOD F, JASKUNAS SR, SHANAFELT AB: FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635, 2005.
14. KHARITONENKOV A, WROBLEWSKI VJ, KOESTER A, CHEN YF, CLUTINGER CK, TIGNO XT, HANSEN BC, SHANAFELT AB, ETGEN GJ: The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148: 774-781, 2007.
15. KHARITONENKOV A, SHANAFELT AB: Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 22: 37-44, 2008.
16. KREMEN J, DOLINKOVA M, KRAJICKOVA J, BLAHA J, ANDERLOVA K, LACINOVA Z, HALUZIKOVA D, BOSANSKA L, VOKURKA M, SVACINA S, HALUZIK M: Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. J Clin Endocrinol Metab 91: 4620-4627, 2006.
17. LUNDASEN T, HUNT MC, NILSSON LM, SANYAL S, ANGELIN B, ALEXSON SE, RUDLING M: PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 360: 437-440, 2007.
18. MAZUREK T, ZHANG L, ZALEWSKI A, MANNION JD, DIEHL JT, ARAFAT H, SAROV-BLAT L, O'BRIEN S, KEIPER EA, JOHNSON AG, MARTIN J, GOLDSTEIN BJ, SHI Y: Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108: 2460-2466, 2003.
19. MRAZ M, BARTLOVA M, LACINOVA Z, MICHALSKY D, KASALICKY M, HALUZIKOVA D, MATOULEK M, DOSTALOVA I, HUMENANSKA V, HALUZIK M: Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71: 369-375, 2009.
20. NISHIMURA T, NAKATAKE Y, KONISHI M, ITOH N: Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206, 2000.
21. VAN DEN BERGHE G, WOUTERS P, WEEKERS F, VERWAEST C, BRUYNINCKX F, SCHETZ M, VLASSELAERS D, FERDINANDE P, LAUWERS P, BOUILLON R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345: 1359-1367, 2001.
22. VAN DEN BERGHE G: Endocrinology in intensive care medicine: new insights and therapeutic consequences. Verh K Acad Geneeskd Belg 64: 167-187, 2002.
23. WENTE W, EFANOV AM, BRENNER M, KHARITONENKOV A, KOSTER A, SANDUSKY GE, SEWING S, TREINIES I, ZITZER H, GROMADA J: Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55: 2470-2478, 2006.
24. ZHANG X, YEUNG DC, KARPISEK M, STEJSKAL D, ZHOU ZG, LIU F, WONG RL, CHOW WS, TSO AW, LAM KS, XU A: Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57: 1246-1253, 2008.